Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

As Patients Age, Future Physicians Develop End Of Life Skills
The American Medical Student Association (AMSA), the nation"s oldest and largest, independent association for physicians-in-training, is pleased to present the graduates of the AMSA Foundation-VITAS End of Life Education Fellowship Program. Five medical students have spent the past six weeks immersing themselves in end of life (EOL) care issues.
generic viagra online
Extreme Sports Not About Risk-taking: Study
Those who think extreme sports are all about risk-taking are missing the point, according to a QUT researcher. Eric Brymer, a lecturer from the School of Human Movement Studies in the Faculty of Health, has been researching whether the element of risk was an important factor among participants in "extreme" sports such as waterfall kayakers, mountain climbers, big wave surfers and B.A.S.E. jumpers.
News of the day
NewYork-Presbyterian/Columbia Implants 100th Heart Valve Replacement Without Open-Heart Surgery
Over the last four years, heart specialists at NewYork-Presbyterian Hospital/Columbia University Medical Center have implanted an innovative aortic heart valve replacement using a catheter-based approach that does not require open-heart surgery in a total of 100 patients -- the most of any U.S. medical center to date.
Endocrinology

Meda: Onsolis Receives FDA Approval

The U.S. Food and Drug Administration (FDA) has approved Onsolis (fentanyl buccal soluble film). This new and patented product is indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Onsolis uses a unique delivery system designed to give rapid and reliable delivery of fentanyl. The product consists of a small dissolvable disc for application of fentanyl to the buccal (inner lining of cheek) membranes. The product is unique and offers an important step to a better pain treatment of cancer patients. "I"m very pleased that Onsolis has been approved for marketing in the U.S. For Meda in the U.S., we get yet another important product addition. The interest among specialists for this new technology is significant, and we are making preparations for product launch during the fourth quarter of 2009. The registration procedures for Onsolis in other key markets are progressing according to plan", said Anders Lç¶nner, CEO Meda. Meda has, in close collaboration with the FDA and Meda"s development partner BioDelivery Sciences Inc, developed the REMS (Risk Evaluation and Mitigation Strategy) program for Onsolis. This REMS program has also been approved by the FDA. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009